24-Valent Pneumococcal Conjugate Vaccine Shows Strong Immune Response in Infants
VAX-24 elicited substantial immunoglobulin G (IgG) and opsonophagocytic assay (OPA) immune responses at 1-month after the third dose across all doses studied.
Positive topline results have been announced from a phase 2 trial evaluating the safety, tolerability and immunogenicity of a 24-valent pneumococcal conjugate vaccine candidate (VAX-24) for the prevention of invasive pneumococcal disease in healthy infants, biotechnology company Vaxcyte announced in a release.1 The company said the data will be used as a basis for a potential phase 3 program.
24-Valent Pneumococcal Conjugate Vaccine Shows Strong Immune Response in Infants / Aleksej - stock.adobe.com
“Despite current vaccination efforts, Streptococcus pneumoniae is the leading cause of vaccine-preventable deaths globally in children under five,” Jim Wassil, Executive Vice President and Chief Operating Officer of Vaxcyte, said in a release.1 “[These] results reinforce our commitment to advancing the broadest-spectrum [pneumococcal conjugate vaccines] to address the substantial invasive pneumococcal disease burden in the infant population, helping to reduce transmission and strengthen community immunity against the consequences of this devastating bacteria.”
READ MORE: Pneumococcal Disease Concerns Remain Despite Successful Vaccine Introduction
The VAX-24 infant study (NCT05844423) is a randomized, observer-blind, active-controlled, dose-finding phase 2 trial evaluating the safety, tolerability and immunogenicity of VAX-24 in infants compared to 20-valnet pneumococcal conjugate vaccine (Prevnar 20). The study cohort includes 802 healthy infants who were aged between 42 and 89 days when enrolled. The study includes 4 arms: a low dose of VAX-24, a mid-dose of VAX-24, a mixed dose of VAX-24, and an active comparator of Prevnar 20.
Patients in the study received injections at 2, 4, 6 and between 12 to 15 months of age. The study found that all of the evaluated doses elicited substantial immunoglobulin G (IgG) and opsonophagocytic assay (OPA) immune responses at 1-month after the third dose. The mid-dose met the target precedent non-inferiority criteria on relative seroconversion rates and also met the target IgG Geometric Mean Ratio point estimate of greater than 0.63 on all currently circulating serotypes contained in VAX-24 after the third dose.
Dose-dependent immune responses were consistently demonstrated at all doses with little to no carrier suppression. Additionally, the data showed the vaccine was well-tolerated and had a similar safety profile to Prevnar 20 across all doses.
Vaxcyte said in the release data for post-dose 4 booster is expected by the end of 2025 and that it anticipates topline data from the VAX-31 infant phase 2 study in mid-2026. The company also said that, depending on the data, it plans to initiate an infant phase 3 study with either VAX-24 or VAX-31.
“Based on the strength of these data, we have selected the mid-dose as the basis of an optimized dose formulation to advance VAX-24 and, pending the VAX-31 phase 2 dose-finding study topline data readout, plan to initiate a phase 3 infant program with either VAX-24 or VAX-31,” Grant Pickering, CEO and Co-Founder of Vaxcyte, said in a release. “These results affirm the potential of our carrier-sparing platform to add coverage and maintain robust immune responses, reinforcing our confidence as we advance our PCVs into adult and infant Phase 3 programs.”
READ MORE: Pneumococcal Resource Center
Are you ready to elevate your pharmacy practice? Sign up today for our free Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips, straight to your inbox.
